🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04187599
Recruiting Not applicable

Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D)

NCT04187599 · tracked via the Priya Life Science China tracker
Sponsor
CooperVision International Limited (CVIL)
Phase
Not applicable
Started
2019-08-29
Last updated
2019-12-05

Condition(s) studied

Myopia

Investigational drug(s) / intervention(s)

Paragon CRT®100 Contact Lens

Paragon CRT®100 Contact Lens: Paragon CRT® 100 Contact Lenses for Corneal Refractive Therapy are indicated for use in the reduction of myopic refractive error in nondiseased eyes.

Study summary

The main objective of this post market clinical study is to evaluate the effectiveness and safety of the Paragon CRT®100 Contact Lens.

Eligibility

Sex
ALL
Min age
8 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: 1. Patient contact lens refraction should fit within the available parameters of the study lenses (spherical power within -4.00D and the cylinder power within 1.50D). 2. Is willing to comply with the wear and visit schedule. 3. Is willing to participate and signed the informed consent form. Exclusion Criteria: 1. Age under 8 years old 2. Any ocular abnormalities, undergone corneal surgery, or history of ocular trauma, active corneal infections (corneal inflammation), corneal curvature less than 40.00D or more than 46.00D 3. Best corrected visual acuity less than 1.0D 4. Pregnant, lactating or near-pregnancy 5. The eye has the following conditions: 1. Acute and subacute inflammations or infection of the anterior segment of the eye 2. Any eye disease, injury, or abnormality that affects the cornea, conjunctiva or eyelids, e.g. dacryocystitis, conjunctivitis, blepharitis and other inflammation, glaucoma, etc. 3. Severe insufficiency of tears (TBUT≤5s). 4. Allergy to any ingredient, such as mercury or thimerosal, in a solution which is to be used to care 5. Any active corneal infection (bacterial, fungal or viral). 6. Manifested strabismus 7. Abnormal intra-ocular pressure 8. Suffering from systemic diseases, resulting in low immunity, or affecting corneal re-shaping (such as acute and chronic sinusitis, diabetes, Down syndrome, rheumatoid arthritis, mental patients, etc.) 9. Under medications or long-term medications that lead to dry eye with clinical signs or affects vision and corneal curvature. 10. Examination result indicate any contraindication or not suitable for OrthoK lens wear 11. Participated in pharmaceutical clinical study 3 months before the date of the screening or participated any other medical devices research study within 30 days of the screening 12. Only eye fulfills inclusion criteria 13. History of any ocular operations 14. Unable to follow investigator's instruction 15. Any other condition not suitable for the study per investigator's judgement

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Changsha Aier Eye Hospital Shanghai China Recruiting
Eye & ENT Hospital of Fudan University Shanghai China Recruiting
Tianjin Eye Hospital Tianjin China Recruiting
The Affiliated Eye Hospital of Wenzhou Medical University Wenzhou China Recruiting

More CooperVision International Limited (CVIL) trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04187599 on ClinicalTrials.gov ↗ ← All trials in China